Introduction: Prostate cancer is a type of cancer that affects men in most parts of the world. After lung cancer, PCa is the second most common cause of death by cancer.PCa is a type of adenocarcinoma. Adenocarcinoma is a type of cancer that develops in epithelial cells that secrete fluids and mucus. Prostate cancer is characterized by slow growth, and it mostly remains in the prostate gland, though some forms of PCa are very aggressive and can metastasize very quickly to nearby organs. PCa is an example of a heterogenous cancer, with the clinical cause of the disease varying greatly. The gland can be categorized into four zones: peripheral zone (PZ), central zone (CZ), transition zone (TZ) and anterior fibromuscular zone (stroma). The peripheral zone is the largest and makes about 70% of the total gland in men. 70 to 85% of PCa occur in this zone. The transition zone is the innermost zone and makes up 5% of the total gland. Benign Prostatic Hyperplasia (BPH) growth occurs in this zone. Age, dietary changes and environmental factors influence the incidence of PCa. A prostate biopsy is considered as the benchmark test for diagnosis of PCa, but the invasive nature of the procedure makes it highly inconvenient to the patient, hence, it is not widely used as a screening test. PSA is the most used biomarker in PCa screening but, it is limited in its ability to exclude benign tumors from malignant tumors. PSA increases with age which has led to the development of age specific PSA ranges.For men in their fourth and fifth decades, the normal range is 0.6 to 0.7ng/ml, for men who are 60 years and above the normal range is 1.0 to 1.5ng/ml, but the cutoff value for PSA is 4.0ng/ml. PSA levels are also elevated in other conditions such as BPH, and prostatitis. Hence, PSA lacks specificity in diagnosis of PCa. To improve detection of PCa, other parameters derived from PSA such as PSA density (PSAD) have been introduced. Method: Serum PSA total was estimated by chemiluminescent immunoassay using the Access 2 immunoassay system. Prostate volume was measured by transabdominal ultrasound and the height, length and width of the prostate was measured. Prostate volume was calculated from these parameters by applying the ellipsoid formula. PSA density was calculated from serum PSA and prostate volume by using the formula: PSAD = serum PSA (ng/ml) / prostate volume (cc). Statistical analysis done on the data obtained using IBM’s SPSS version 29.0 and Microsoft Excel 365 Results: It was observed that prostate volume and serum PSA total increase with age. Prostate volume and PSA showed a strong and significant correlation, with ap value of 0.001 (at p<0.05) and a Pearson correlation of r = 0.39. similarly, PSA and PSAD have a strong and significant correlation, with a p value of 0.001 (at p<0.05) and a Pearson correlation value of r = 0.84. Conclusion: From the above result it was concluded that PSA density is sensitive than PSA total at predicting prostate cancer especially at PSA levels greater than 4ng/ml.